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Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival
H ospital-acquired pneumonia (HAP) is the second most common nosocomial infection in the United States and is a leading cause of mortality among hospital-acquired infections (1) . The rate of HAP is thought to be between 5 and 10 cases per 1,000 admissions in the United States, with the incidence of ventilatorassociated pneumonia (VAP) being much higher (1) . Data for HAP in Europe are limited, but rates have been estimated to be approximately 3 cases per 1,000 admissions (2) . The mortality rate for HAP is high, reaching Ͼ50% for VAP in some settings (3) . Underlying severe renal impairment has been associated with an excess risk of hospital mortality. In a study of 471 patients admitted to a medical intensive care unit (ICU), acute renal failure was shown by multivariate logistic regression analyses to be an independent predictor of mortality (adjusted odds ratio, 3.7; 95% confidence interval [CI], 2.2 to 6.1) (4) . In a much larger study of Ͼ17,000 patients admitted to an ICU and requiring renal replacement therapy for acute renal failure, the mortality rate was increased 4-fold (5) .
In recent years, there has been a substantial increase in the number cases of pneumonia attributable to multidrug-resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), which accounts for between 20 and 40% of all HAP and VAP cases (6) . Shortcomings associated with the limited number of currently approved treatments for MRSA pneumonia support the need for new treatment options (7) .
Telavancin is a lipoglycopeptide antibacterial agent with a dual mechanism of action that combines inhibition of cell wall synthesis and disruption of bacterial cell membrane function (8) . Telavancin has demonstrated in vitro bactericidal activity against a range of clinically important Gram-positive bacteria, including MRSA (9, 10) . Telavancin is approved in the United States and Canada for treatment of adult patients with complicated skin and skin structure infections caused by susceptible Gram-positive pathogens, in the United States for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia due to S. aureus (methicillin-susceptible and -resistant isolates) when other alternatives are unsuitable, and in Europe for treatment of MRSA nosocomial pneumonia when other alternatives are unsuitable. (At the time of submission, the telavancin European marketing authorization for the treatment of nosocomial pneumonia was suspended pending evidence of a new European Medicines Agency-approved supplier. Clinigen Healthcare Ltd., Theravance's commercialization partner for telavancin in Europe, is in the process of seeking approval of a new manufacturing source.)
In two methodologically identical, randomized ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, telavancin was shown to be noninferior to vancomycin for treatment of patients with HAP due to Grampositive pathogens (11) . Telavancin cure rates were higher than those of vancomycin in clinically evaluable patients with S. aureus as the sole baseline pathogen isolated and in patients infected with S. aureus with vancomycin MICs of Ն1 g/ml (11) . Safety findings were comparable for the two treatment groups, while onstudy mortality rates were Ͻ2% higher in the telavancin group than in the vancomycin group, although this difference was not statistically significant (11) .
Draft U.S. Food and Drug Administration (FDA) guidance published in 2010 (12) proposed that the inclusion criteria for new clinical studies of treatments for bacterial HAP be modified to include specific diagnostic criteria based on management guidelines developed by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) (1) . The ATS/IDSA guidelines suggest that HAP should be suspected if a patient has the presence of a new or progressive radiographic infiltrate together with clinical findings suggesting infection, which include new onset of fever, purulent sputum, and leukocytosis/leukopenia (1) . In addition to recommending the adoption of specific inclusion criteria based on ATS/IDSA guidelines, the draft FDA guidance proposed a primary endpoint of 28-day all-cause mortality, rather than clinical cure, for trials of treatments for HAP (12) .
To evaluate the effect of applying the ATS/IDSA diagnostic criteria, the revised inclusion criteria from the draft FDA guidance, and the proposed 28-day all-cause mortality endpoint on the ATTAIN study findings, a post hoc analysis was performed, exploring clinical response and 28-day survival endpoints.
(Most of these analyses were presented at the FDA Anti-Infective Drugs Advisory Committee on 28 November 2012 in support of the evaluation of the safety and efficacy of telavancin for the treatment of hospital-acquired bacterial pneumonia/ventilatorassociated bacterial pneumonia due to Gram-positive pathogens.)
MATERIALS AND METHODS
This was a post hoc analysis of data from two identical, randomized, double-blind, comparator-controlled, parallel-group, phase III ATTAIN clinical trials (study 0015, [NCT00107952] and study 0019 [NCT00124020]), based on supplemental mortality data obtained after study completion. After FDA affirmation that mortality was viewed as an important efficacy variable, the sponsor sought additional patient follow-up to day 28 postrandomization to support a day 28 landmark survival endpoint. This supplemental poststudy mortality status follow-up was successful in obtaining complete 28-day follow-up for approximately 95% of all patients. The remaining 5% were censored at the point of last follow-up prior to day 28.
Details of the study design, methods, and results have been reported previously (11) , without the supplemental mortality data or the description of the ATS/IDSA population. In brief, male and nonpregnant female patients aged Ն18 years were eligible for enrollment if they had pneumonia acquired after 48 h in an inpatient acute-or chronic-care facility or that developed within 7 days of discharge. This included hospitalized patients with VAP who developed pneumonia de novo after at least 48 h of mechanical ventilation. Eligible patients were randomized 1:1 to receive either 10 mg of telavancin/kg of body weight intravenously every 24 h or 1 g of vancomycin intravenously every 12 h for 7 to 21 days. The vancomycin dosage could be modified per site-specific procedures for body weight and/or renal function as well as vancomycin trough level monitoring, as long as the study blind was maintained.
Patients were assessed at baseline and daily throughout study treatment, at the end of therapy, and at the follow-up/test-of-cure (FU/TOC) visit. FU/TOC assessment was performed 7 to 14 days following the end of therapy. The prespecified primary endpoint was clinical response at the FU/TOC visit, defined as follows. Cure was defined as an improvement or lack of progression of baseline radiographic findings at the end of therapy (EOT) and resolution of signs and symptoms of pneumonia at FU/TOC. Failure was defined as persistence or progression of signs and symptoms or progression of radiological signs of pneumonia at EOT, termination of study medications due to "lack of efficacy" and initiation within 2 calendar days of a different potentially effective antibiotic, death on or after day 3 attributable to primary infection, or relapsed infection at the TOC visit after termination of study medications. An indeterminate response was defined as the inability to determine outcome.
The study protocol for the ATTAIN studies was approved by the institutional review board at each site, and the studies were conducted in accordance with the Declaration of Helsinki. All patients, or their authorized representatives, provided written informed consent.
Analysis populations. The all-treated (AT) population from the two ATTAIN studies comprised all patients who received at least one dose of randomized treatment (11) . The ATS/IDSA criteria (presence of new or progressive radiographic infiltration plus two of the following clinical features: fever of Ͼ38°C, white blood cell count of Ͼ10,000 or Ͻ4,500/mm 3 , and purulent secretions [1] ) were applied in a blind, programmatic fashion to the AT group from the ATTAIN studies to derive the refined all-treated population (ATS/IDSA-AT group). Additional analysis populations were the clinically evaluable (CE) (per-protocol) subgroup of the ATS/IDSA-AT group (ATS/IDSA-CE group), the ATS/ IDSA-AT-GP group (patients in the ATS/IDSA-AT group with at least one Gram-positive baseline respiratory pathogen isolated), and the ATS/ IDSA-AT-GPO group (patients in the ATS/IDSA-AT group with only Gram-positive baseline pathogens isolated, excluding patients with mixed Gram-positive/Gram-negative infections). The latter two groups are of scientific and regulatory interest because the outcome addresses efficacy in patients with targeted telavancin-susceptible organisms.
Statistical analysis. The primary objective of this post hoc analysis was to assess the clinical response at the FU/TOC visit in patients who met the ATS/IDSA diagnostic criteria. Differences in cure rates between the telavancin and vancomycin treatment groups were calculated, together with two-sided 95% CIs. Consistent with the original statistical analysis plan, aggregated analyses of the ATTAIN trials were performed on the basis that these two studies had identical protocol designs and were conducted in approximately the same time frame. Evaluation of clinical response in the current analysis was done according to the protocol's prespecified noninferiority margin for a difference in clinical response (telavancin-vancomycin) of Ϫ20%, as used in the previously successful HAP trials that led to registration (13) . A secondary objective of this analysis was to assess between-group differences in survival at 28 days in the ATS/IDSA-AT population. Treat-ment-specific estimates of overall 28-day survival were based on Kaplan-Meier curves. Differences between treatments and corresponding twosided 95% CIs at day 28 were calculated.
Given the previously noted increased risk of death in critically ill patients in association with severe renal impairment and the reduced efficacy seen with telavancin in patients with preexisting moderate or severe renal impairment and complicated skin and skin structure infections, the survival results, as well as clinical cure results, were stratified by degree of renal impairment (moderate, with a creatinine clearance [CL CR ] value of 30 to Ͻ50 ml/min, or severe, with a CL CR value of Ͻ30 ml/min). Creatinine clearance was estimated by using the Cockcroft-Gault equation. No multiplicity adjustments were made for the multiple statistical comparisons reported here. The enrolled patients in the combined ATS/IDSA-AT group provided statistical power of 99% (study 0015, 88%; study 0019, 90%) to demonstrate noninferiority of telavancin relative to vancomycin for 28-day survival, with a noninferiority margin of Ϫ10%.
RESULTS

Analysis population.
The ATS/IDSA-AT group comprised 86% of the original ATTAIN AT group (1,289/1,503) ( Table 1) . Approximately 13% of the original ATTAIN AT telavancin group and 11% of the vancomycin group had chest X-ray findings and only one clinical feature (primarily purulent sputum); Ͻ2% of patients in each group had only chest X-ray changes.
The baseline demographics and characteristics of the ATS/ IDSA-AT group are shown in Table 2 . Frequencies of baseline comorbidities such as diabetes mellitus, chronic obstructive pulmonary disease, and acute/chronic renal failure were similar between the study and treatment groups. The one notable difference was that the frequency of vasopressor use at baseline in the vancomycin group was almost twice as high as that in the telavancin group in both populations (13% versus 7%). Baseline demographics and characteristics were similar to those of the overall ATTAIN AT population.
The majority of baseline bacterial isolates (91%) were obtained from respiratory specimens only. The remaining isolates were re- (Table 3) . Mixed Gram-positive/Gram-negative infections were identified in 26% (244/951) of ATS/IDSA-AT patients who had a baseline pathogen identified. Efficacy. For the primary efficacy analysis endpoint of clinical response at FU/TOC visit, noninferiority was supported in both the ATS/IDSA-AT and ATS/IDSA-CE analysis groups for studies 0015 and 0019 separately and when the studies were pooled, with the lower limit of the 95% CIs for all treatment group differences exceeding the prespecified Ϫ20% margin and also above Ϫ10% (Table 4 ). Cure rates were 59% (376/634) and 59% (386/655) for telavancin and vancomycin, respectively, in the ATS/IDSA-AT group and 83% (218/263) and 80% (238/297), respectively, in the ATS/IDSA-CE group (both studies combined) ( Table 4 ).
In patients with only S. aureus isolated at baseline, cure rates observed for telavancin were higher than those observed for vancomycin in the ATS/IDSA-CE group (86% versus 75%; 95% CI for the difference, 1.2% to 20.8%). The higher cure rates for telavancin were consistent in patients with MRSA, methicillin-susceptible S. aureus (MSSA), or S. aureus strains with MICs of vancomycin of Ն1 g/ml, although these differences were not statistically significant owing to smaller sample sizes ( Table 5) . Cure rates were lower (although not statistically significantly so) in patients with mixed infections (Gram-positive and Gram-negative pathogens) in the telavancin group.
When the clinical cure rate was assessed according to baseline CL CR , numerically lower cure rates with telavancin were observed in patients with baseline CL CR values of Ͻ50 ml/min. Of note, regardless of renal function, cure rates in the telavancin group were higher in patients with only Gram-positive pathogens isolated at baseline than in the overall AT population ( Table 6) .
Analysis of survival at 28 days. The analysis of survival at 28 days revealed similar survival rates between the two treatment groups across the two studies ( Fig. 1 ). Lower survival rates (Kaplan-Meier estimates) were observed for patients treated with telavancin than for patients treated with vancomycin who had moderate-to-severe (CL CR , Ͻ50 ml/min) (59% and 70%, respectively) or severe (CL CR , Ͻ30 ml/min) (47% and 61%, respectively) renal insufficiency (Fig. 2 ). For patients with CL CR values of Ն50 ml/min, the survival rate at 28 days for the telavancin group was similar to that for the vancomycin group (84% and 81%, respectively).
Safety. The overall safety findings of the ATTAIN trials were described in detail previously (11) . In the ATS/IDSA-AT population, 82% (519/636) of the telavancin group and 81% (532/653) of the vancomycin group experienced at least one adverse event (AE), and 30% (193/636) of the telavancin group and 27% (176/ 653) of the vancomycin group experienced a serious AE. Discontinuations due to AEs were reported for 8% (51/636) of telavancin-treated patients and 5% (34/653) of vancomycin-treated patients. The incidences of individual AEs were similar in the two treatment groups, with diarrhea, anemia, hypokalemia, and constipation being the most common (Ͼ5%) in both treatment groups. Renal AEs (failure, impairment, insufficiency, or elevations in serum creatinine levels) occurred in 9% (59/636) and 8% (51/653) of telavancin-and vancomycin-treated patients, respectively. Among patients with normal baseline renal function, potentially clinically significant increases in serum creatinine levels (maximum value of Ն1.33 mg/dl and at least a 50% increase from baseline) occurred in 14% (71/505) of the telavancin group and in 10% (50/523) of the vancomycin group.
DISCUSSION
The ATTAIN studies were two methodologically identical, randomized, phase III studies that demonstrated the noninferiority of telavancin relative to vancomycin for the treatment of HAP, including VAP, due to Gram-positive organisms on the basis of clinical response (11) . In this post hoc analysis, the ATS/IDSA HAP diagnostic criteria were applied to the AT study group from the ATTAIN studies to evaluate the potential effect on clinical outcomes. The results of this analysis support the noninferiority of telavancin relative to vancomycin with regard to clinical response when the ATS/IDSA diagnostic criteria were applied. Further-more, our analysis suggests that patients with infections due solely to S. aureus (MRSA or MSSA) treated with telavancin had higher cure rates than such patients treated with vancomycin. This may be related to a better in vitro activity of telavancin against S. aureus, including strains with higher vancomycin MICs. Given these findings, it would be appropriate to consider telavancin as a therapeutic option for the management of pneumonia due to S. aureus (MRSA and MSSA) in patients without moderately to severely compromised renal function and as potentially useful in patients with compromised renal function if no other suitable alternatives are available. Antibiotic resistance poses a significant risk to public health. The incidence of MRSA continues to increase (6) have also emerged (14, 15) . The previously reported results of the ATTAIN studies suggested that telavancin was potentially more effective than vancomycin in patients infected with S. aureus strains with vancomycin MICs of Ն1 g/ml (11) . Although not statistically significant (owing to a smaller sample size of patients), the same trend was observed in this analysis, with a similarly large and clinically meaningful difference in cure rates between the treatment groups. Therefore, telavancin may be a reasonable empirical therapeutic option in centers with high rates of S. aureus with elevated vancomycin MICs. Analysis of 28-day all-cause survival showed similar survival rates between telavancin-treated and vancomycin-treated patients, although our analysis did highlight lower survival rates in patients with moderate or severe renal dysfunction who received telavancin than in those who received vancomycin. The mechanism of this increased risk is unclear, and interpretation of mortality as an endpoint of HAP is confounded by nonattributable mortality, which may be the result of variables that are unrelated to pneumonia. The ATTAIN studies evaluated clinical outcome as the primary endpoint and thus excluded only cases where death was expected within 7 days. However, despite appropriate dosage adjustments for renal function, nephrotoxicity due to telavancin in patients with preexisting renal impairment cannot be ruled out as a contributing factor. The use of telavancin in patients with CL CR values of Ͻ50 ml/min should therefore be considered only when the benefits outweigh any potential risks or if other alternatives are not suitable. Monitoring of renal function in these patients should be performed routinely (11) .
Limitations of this study include the fact that it is a post hoc analysis. The ATS/IDSA criteria were, however, applied programmatically in a blind fashion. Using these criteria, it was possible to ensure that the patients included in the analysis were those most likely to have pneumonia. However, each of the analyses used a subgroup of the original ATTAIN study population, with decreasing numbers of patients in each analysis group potentially reduc-ing the power of the analysis to demonstrate noninferiority. That said, the all-treated group retained a sufficient sample size to ensure adequate statistical power. The 28-day mortality endpoint, while potentially confounded by nonattributable mortality, is an objective outcome measure and, in these studies, identified a group of patients for whom caution should be taken when considering the use of telavancin.
Conclusions. The results of this reanalysis of the ATTAIN patient population suggest that telavancin is noninferior to vancomycin for clinical cure of HAP, including VAP, due Gram-positive organisms when the ATS/IDSA diagnostic criteria are applied. In this analysis, cure rates against S. aureus were numerically higher than those with vancomycin for both MRSA and MSSA infections, suggesting that telavancin is an effective therapy for HAP due to S. aureus, including cases caused by S. aureus strains with high or unknown vancomycin MICs. The use of telavancin in patients with preexisting moderate-to-severe renal function should be considered only if the benefits of treatment outweigh the risks or in the absence of other suitable alternatives.
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